



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
25 September 2026
9 September 2026

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Lewis George Gradon
Fisher & Paykel Healthcare Corporation Limited
Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Performance Share Rights
b) Options to Acquire Ordinary Shares
c) Ordinary Shares
Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 208,815 Performance Share Rights
b) 198,657 Options to acquire Ordinary Shares
c) 558,934 Ordinary Shares
a) 159,565 Performance Share Rights
b) 85,480 Options to acquire Ordinary Shares
c) 565,961 Ordinary Shares
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust
a) Lewis George Gradon
b) Lewis George Gradon
c) Lewis George Gradon; Gradon Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal


Total number of transactions to which notice relates:

Five

Details of transactions requiring disclosure-

Date of transaction:

a) 21 September 2026
b) 21 September 2026
c) 23 September 2026
d) 23 September 2026
e) 24 September 2026

	a) Exercise of Performance Share Rights and Issue of Ordinary Shares b) Sale of Ordinary Shares c) Exercise and cancellation of Options and Issue of Ordinary Shares d) Sale of Ordinary Shares e) Sale of Ordinary Shares
Nature of transaction:	
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	a) Nil b) \$44.5340 per Ordinary Share c) Exercise price of \$21.96 per Ordinary Share d) \$45.0368 per Ordinary Share e) \$44.8037 per Ordinary Share
	a) Exercise of 49,250 Performance Share Rights and Issue of 49,250 Ordinary Shares b) Sale of 50,000 Ordinary Shares c) Exercise of 113,177 Options and Issue of 57,777 Ordinary Shares d) Sale of 18,138 Ordinary Shares e) Sale of 31,862 Ordinary Shares
Number of financial products to which the transaction related:	
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	25 September 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary